Mom 20and 20baby
Apt 20logo

Advanced Prenatal Therapeutics, Inc. (APT)

APT is developing a patented medical device specifically designed to treat preeclampsia in pregnancy, a leading cause of maternal and fetal death worldwide.

  • Stage Prototype Ready
  • Industry Medical Devices and Equipment
  • Location Laguna Hills, CA, USA
  • Currency USD
  • Founded September 2012
  • Employees 4
  • Incorporation Type C-corp
  • Website

Company Summary

APT is developing a Targeted Apheresis Column for Preeclampsia (TAC- PE) to be used to specifically and safely remove pathogenic factors associated with preeclampsia from the blood of pregnant mothers. Removing these factors could lead to prolonged pregnancy, improved fetal outcomes, and decreased risk associated with preterm birth. APT's TAC-PE could become the standard of care for treating this virtually unmet need.


  • Default avatar
    James Smith, Ph.D.
    President / CEO

    Dr. Smith has over 15 years of experience in regulatory affairs and development of novel technologies from concept through commercialization. He is experienced in all aspects of regulatory affairs, quality and data management systems, supervision of R&D, development of new product specifications, and with evaluating and registering medical drug and device product lines. Ph.D. in Pharmacology and Toxicology from University of California, Irvine.

  • Default avatar
    Henry Smith, Ph.D.
    Chairman of the Board

    Dr. Smith has over 40 years of experience in the healthcare industry. Co-founder of several biotechnology companies and medical laboratories including NanoSmart Pharmaceuticals, Epinex Diagnostics, Allied Biotechnology International, and Associated Reference Laboratories. Senior management in medical reference laboratories including Specialty Labs and BioScience Laboratories. Ph.D. Immunology from University of Leeds Medical School, England.

  • 14910ed5 6af9 4935 a54b 6cafbddbfdf7
    VP Business Development

    Mr. Thiel has over 12 years experience in management positions in the biotechnology industry providing services in business development, fund raising, investor relations, marketing and PR for early-stage development companies. Mr. Thiel received his B.S. in Business from Miami University, Ohio, with a concentration in international business at Universidad de Las Americas, in Puebla, Mexico.


  • Default avatar
    Nihar Niyak, D.V.M., Ph.D.
    Default avatar
    Vijay Mahant, M.S., Ph.D.

Previous Investors

  • Default avatar
    Default avatar
    Private Accredited Investors